Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)

Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13–14

HOS-134491 · Präparat HOS-097580

13 INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS Medicinal products by Interaction Geometric mean change Recommendations concerning co- therapeutic areas (%) administration Dabigatran etexilate dabigatran etexilate (150 mg): Darunavir/ritonavir: Edoxaban darunavir/ritonavir 800/100 mg Clinical monitoring and/or dose single dose: reduction of the DOAC should be dabigatran AUC ↑ 72% considered when a DOAC dabigatran Cmax ↑ 64% transported by P-gp but not metabolised by CYP3A4, including darunavir/ritonavir 800/100 mg dabigatran etexilate and edoxaban, once daily: is co-administered with dabigatran AUC ↑ 18% Darunavir/rtv. dabigatran Cmax ↑ 22% Ticagrelor Based on theoretical considerations, Concomitant administration of co-administration of boosted darunavir boosted darunavir with ticagrelor is with ticagrelor may increase contraindicated (see section 4.3). concentrations of ticagrelor (CYP3A and/or P-glycoprotein inhibition).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) dabigatran (HOS-112096) edoxaban (HOS-086234) ritonavir (HOS-084521) dabigatran etexilate (HOS-086233)